Ignite Creation Date:
2024-10-26 @ 3:37 PM
Last Modification Date:
2024-10-26 @ 3:37 PM
Study NCT ID:
NCT06555068
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-08-01
Brief Title:
A Trial of HRS-6209 in Combination With Fulvestrant Letrozole HRS-8080 or HRS-1358 in Breast Cancer Patients
Sponsor:
None
Organization:
None
Study Overview
Official Title:
An Open-Label Multi-Center Phase IbII Clinical Study Evaluating the Safety Tolerability Pharmacokinetics and Preliminary Efficacy of HRS-6209 in Combination With Fulvestrant Letrozole HRS-8080 or HRS-1358 in Patients With Advanced Unresectable or Metastatic Breast Cancer
Status:
RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The study is being conducted to evaluate the safety PK and efficacy of HRS-6209 in Combination with Fulvestrant Letrozole HRS-8080 or HRS-1358 for advanced unresectable or metastatic breast cancer
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None